Tamoxifen Citrate is a selective estrogen receptor modulator supplied as a 50 mg/ml liquid research compound in a 30 ml bottle. It is designed for controlled laboratory studies involving estrogen receptor activity, endocrine signalling and associated metabolic pathways.
The liquid format provides a consistent and clearly measured concentration for use within established laboratory protocols.
Storage: Store below 25°C and keep the container tightly closed.
Classification: Laboratory research compound.
Important: For laboratory research only. Not intended for human or veterinary use.
Tamoxifen Citrate is a selective estrogen receptor modulator supplied as a 50 mg/ml liquid research compound in a 30 ml bottle. It is designed for controlled laboratory studies involving estrogen receptor activity, endocrine signalling and associated metabolic pathways.
The liquid format provides a consistent and clearly measured concentration for use within established laboratory protocols.
Storage: Store below 25°C and keep the container tightly closed.
Classification: Laboratory research compound.
Important: For laboratory research only. Not intended for human or veterinary use.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Not a researcher? Exit
